Skip to main content
Back to all tickers

Marker Therapeutics, Inc. (MRKR) stock forecast & analysis

1.09

NasdaqCM · USDDelayed by 15 minutes

Down: -0.23, -17.4%

1.01Down: -0.08, -7.2%

1 analysis

Use Arrow keys to explore price history; Home and End jump to the oldest and newest points
Price history for MRKR.US from 10-23 11:00 to 11-21 00:55 with 1 analysis run marked; public runs are shown as stance-colored dots (Bullish, Bearish, or Neutral) and gated runs as a lock icon (sign in to read). Each marker is a link to sign in.BullishBearishNeutralLocked · sign in to read

Latest analysis: · verdict locked

Open
1.34
Previous close
1.32
Day range
1.09 – 1.45
52-week range
0.8100 – 2.46
Volume (shares)
1.90M
Net assets
Not available
Expense ratio
Not available
Shares outstanding
16.67M
P/E ratio
Not available
Dividend yield
0.00%
Beta
Not available
Market cap
18.17M
Market Scanner’s AI analysis of Marker Therapeutics, Inc. (MRKR), updated November 2026: Marker Therapeutics' recent coverage focused on a significant CPRIT grant and a sharp price increase, alongside technical indicators.

This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Marker Therapeutics, Inc. (MRKR) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.

Summary

Marker Therapeutics' recent coverage focused on a significant CPRIT grant and a sharp price increase, alongside technical indicators.

Recent analyses for MRKR covered a substantial $16.2 million grant from the Cancer Prevention and Research Institute of Texas to advance MT-601 into a Phase 2 study. This non-dilutive funding was noted as a potential runway extender. The stock experienced a significant price surge, closing at $1.32 after opening at $1.02 and trading between $0.98 and $1.68, representing a 55% gain from the prior session. Technical indicators such as the 50-day and 200-day moving averages were also examined.

MRKR news & sentiment

News coverage highlighted a significant non-dilutive grant award, which was seen as a positive development for extending the company's runway. Social media discussion was not covered in the provided notes.

MRKR technical picture

The stock closed at $1.32 following a significant 55% single-day gain on high volume. Momentum readings were mixed, with RSI elevated but MACD showing slight downward pressure. The price traded above its 50-day and 200-day moving averages, with the 50-day below the 200-day.

Fundamentals

The analysis covered Marker Therapeutics' market capitalization and share count, noting a lack of dividend payments. It also examined the stock's trading position relative to its 52-week range and its 50-day and 200-day moving averages, observing that the price had recently moved above the 200-day average.

Factors discussed — upside

  • Awarded $16.2 million CPRIT grant for MT-601 Phase 2 study
  • Grant funding is non-dilutive, potentially extending runway
  • Significant single-day price increase of 55%
  • Price trading above 50-day and 200-day moving averages

Factors discussed — risks

  • 50-day moving average below 200-day moving average indicates prior downtrend structure
  • Grant terms regarding disbursement schedule, co-funding, or milestones not disclosed
  • Grant funding
  • Price action
  • Technical indicators
  • Clinical development

Summary updated .

MRKR technical indicators

Common technical indicators for MRKR, computed from its daily closing prices.

IndicatorValueReading
50-day simple moving average1.03Price above
10-day exponential moving average0.99Price above
Relative strength index (14-day)54.52Neutral
MACD line (12/26/9)-0.0038Above its signal line
Bollinger bands (20-day, 2σ)0.74 – 1.17Price inside the bands

Analyses

Recent MRKR.US analyses are locked — sign in to read them or generate a fresh one.

CaseDescriptionDate

Frequently asked questions

What is the bull case for Marker Therapeutics, Inc.?
The bull case for MRKR centers on a significant non-dilutive $16.2 million grant from CPRIT to advance MT-601, which could extend the company's runway. This was accompanied by a notable 55% single-day price increase, with the stock trading above key moving averages.
What are the risks for Marker Therapeutics, Inc.?
Risks for MRKR include the technical structure indicating a prior downtrend, as the 50-day moving average remains below the 200-day average. Additionally, details surrounding the grant's disbursement schedule and conditions were not disclosed.
Is Marker Therapeutics, Inc. bullish or bearish?
Recent AI analyses of Marker Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for MRKR centers on a significant non-dilutive $16.2 million grant from CPRIT to advance MT-601, which could extend the company's runway. This was accompanied by a notable 55% single-day price increase, with the stock trading above key moving averages. Discussed risks: Risks for MRKR include the technical structure indicating a prior downtrend, as the 50-day moving average remains below the 200-day average. Additionally, details surrounding the grant's disbursement schedule and conditions were not disclosed. These are descriptive observations, not a recommendation.
What is the latest sentiment on Marker Therapeutics, Inc.?
News coverage highlighted a significant non-dilutive grant award, which was seen as a positive development for extending the company's runway. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Marker Therapeutics, Inc.?
Every analysis of Marker Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Marker Therapeutics, Inc.?

The bull case for MRKR centers on a significant non-dilutive $16.2 million grant from CPRIT to advance MT-601, which could extend the company's runway. This was accompanied by a notable 55% single-day price increase, with the stock trading above key moving averages.

What are the risks for Marker Therapeutics, Inc.?

Risks for MRKR include the technical structure indicating a prior downtrend, as the 50-day moving average remains below the 200-day average. Additionally, details surrounding the grant's disbursement schedule and conditions were not disclosed.

Is Marker Therapeutics, Inc. bullish or bearish?

Recent AI analyses of Marker Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for MRKR centers on a significant non-dilutive $16.2 million grant from CPRIT to advance MT-601, which could extend the company's runway. This was accompanied by a notable 55% single-day price increase, with the stock trading above key moving averages. Discussed risks: Risks for MRKR include the technical structure indicating a prior downtrend, as the 50-day moving average remains below the 200-day average. Additionally, details surrounding the grant's disbursement schedule and conditions were not disclosed. These are descriptive observations, not a recommendation.

What is the latest sentiment on Marker Therapeutics, Inc.?

News coverage highlighted a significant non-dilutive grant award, which was seen as a positive development for extending the company's runway. Social media discussion was not covered in the provided notes.

How does Market Scanner analyse Marker Therapeutics, Inc.?

Every analysis of Marker Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.

Read the methodology

Bundles used
claude-medium-v2

Run a fresh MRKR.US analysis

Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.

Or read 1 earlier report



Most analyzed tickers